AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21956725 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 0.25 mg/kg/day
Number of subjects: 238
Study 21956725 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 0.5 mg/kg/day
Number of subjects: 238
Study 21956725 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 1.0 mg/kg/day
Number of subjects: 238
Study 21956725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 18945226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 24
Study 18945226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17077731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion group (n = 30)
Number of subjects: 58
Study 17077731 — intervention group
Group type: COMPARATOR
Intervention: Nonfusion group (n = 28)
Number of subjects: 58
Study 15022370 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received coping skills training)
Number of subjects: 41
Study 15022370 — intervention group
Group type: COMPARATOR
Intervention: Control group (received nutrition education and exercise training only)
Number of subjects: 41
Study 11506443 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lenses
Number of subjects: 26
Study 10335771 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors plus statins (lovastatin or pravastatin)
Number of subjects: 0
Study 10335771 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors alone
Number of subjects: 0
Study 7664703 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazemuls with pethidine (50 mg)
Number of subjects: 71
Study 7664703 — intervention group
Group type: COMPARATOR
Intervention: Diazemuls alone (placebo)
Number of subjects: 71
Study 7664703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 2751276 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox TC administered 0.5 h before enoxacin
Number of subjects: 10
Study 2751276 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox TC administered 2 h before enoxacin
Number of subjects: 10
Study 2751276 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox TC administered 8 h before enoxacin
Number of subjects: 10
Study 2751276 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox TC administered 2 h after enoxacin
Number of subjects: 10
Study 2751276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine administered intravenously 2 h before enoxacin
Number of subjects: 10
Study 947523 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy
Number of subjects: 467
Study 947523 — intervention group
Group type: COMPARATOR
Intervention: Extended field radiotherapy
Number of subjects: 467
Study 31992277 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique with membrane fixation (using periosteal sutures)
Number of subjects: 28
Study 31992277 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique without membrane fixation
Number of subjects: 28
Study 31188779 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-Emotive Behavior Therapy (REBT)
Number of subjects: 30
Study 31188779 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 28858362 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (18 g containing 300 mg CGA in 200 mL hot water)
Number of subjects: 12
Study 28858362 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (18 g containing 287 mg CGA in 200 mL hot water)
Number of subjects: 12
Study 28858362 — intervention group
Group type: COMPARATOR
Intervention: Hot water (control)
Number of subjects: 12
Study 28858362 — intervention group
Group type: COMPARATOR
Intervention: Caffeinated coffee, decaffeinated coffee, and hot water (control)
Number of subjects: 12
Study 25944073 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX with on-demand MDZ
Number of subjects: 80
Study 25944073 — intervention group
Group type: COMPARATOR
Intervention: MDZ alone
Number of subjects: 80
Study 22127508 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum level of under-carboxylated osteocalcin (ucOC)
Number of subjects: 334
Study 22127508 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ucOC expressed as percentage of total osteocalcin level
Number of subjects: 334
Study 21282825 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H5N1 vaccine (3.75 microgram H5N1 haemagglutinin + AS03(A))
Number of subjects: 360
Study 21282825 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted H5N1 vaccine (3.75 microgram H5N1)
Number of subjects: 360
Study 19375519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mesalamine 2 g once daily
Number of subjects: 362
Study 19375519 — intervention group
Group type: COMPARATOR
Intervention: Oral mesalamine 1 g twice daily
Number of subjects: 362
Study 19375519 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 362
Study 16391575 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1 g) and Vitamin D3 (800 IU) supplementation once daily for 1 year
Number of subjects: 23
Study 16391575 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (Control group)
Number of subjects: 23
Study 12633544 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 400
Study 12633544 — intervention group
Group type: COMPARATOR
Intervention: Stenting preceded by balloon predilatation
Number of subjects: 400
Study 10842553 — intervention group
Group type: COMPARATOR
Intervention: Daily iron/folate supplement (60 mg iron/0.25 mg folate per day)
Number of subjects: 413
Study 10842553 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron/folate supplement (120 mg iron/0.50 mg folate once a week)
Number of subjects: 413
Study 9378838 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0
Study 9378838 — intervention group
Group type: COMPARATOR
Intervention: Treatment B
Number of subjects: 0
Study 8518219 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA (medroxyprogesterone acetate) 500 mg i.m. daily for 28 days, then 500 mg i.m. twice weekly for 5 months
Number of subjects: 408
Study 8518219 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA (medroxyprogesterone acetate)
Number of subjects: 408
Study 8518219 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA+ group
Number of subjects: 408
Study 8518219 — intervention group
Group type: COMPARATOR
Intervention: MPA- group
Number of subjects: 408
Study 3830118 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg)
Number of subjects: 20
Study 3830118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29446548 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-h combined physical and psychological treatment programme
Number of subjects: 373
Study 27530188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg once daily for 7 days, edoxaban on day 4
Number of subjects: 3
Study 27530188 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg four times daily for 8 days, edoxaban on day 7
Number of subjects: 3
Study 27530188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 500 mg single dose with edoxaban
Number of subjects: 3
Study 27530188 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban alone
Number of subjects: 3
Study 24460597 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientated tour with mother of the operation room the night before surgery
Number of subjects: 70
Study 24460597 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative care (Control)
Number of subjects: 70
Study 24460597 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientated tour (Intervention)
Number of subjects: 70
Study 23286674 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program via surface mail providing information on influenza vaccine effectiveness and safety (EPG)
Number of subjects: 2402
Study 23286674 — intervention group
Group type: COMPARATOR
Intervention: No intervention (NPG)
Number of subjects: 2402
Study 23286674 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program via surface mail (EPG)
Number of subjects: 2402
Study 20636229 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (n=39)
Number of subjects: 78
Study 20636229 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=39)
Number of subjects: 78
Study 18300707 — intervention group
Group type: EXPERIMENTAL
Intervention: Muller maneuver (MM) with videoendoscopy
Number of subjects: 70
Study 16336797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (10 ml) applied at the end of breast resection plus closed suction drains
Number of subjects: 43
Study 16336797 — intervention group
Group type: COMPARATOR
Intervention: Control group (drain system only)
Number of subjects: 43
Study 12827575 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) with fentanyl, propofol, rocuronium (n = 37)
Number of subjects: 72
Study 12827575 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia with meperidine (TEA-M) (2 mg/kg in 10-12 mL) (n = 35)
Number of subjects: 72
Study 10583037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 0
Study 10583037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol plus losartan
Number of subjects: 0
Study 10583037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (electrolyte solution)
Number of subjects: 0
Study 8722359 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive antiviral therapy with ganciclovir
Number of subjects: 58
Study 8722359 — intervention group
Group type: COMPARATOR
Intervention: Matched historical controls
Number of subjects: 58
Study 1725620 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet concentrates from AS-104
Number of subjects: 115
Study 1725620 — intervention group
Group type: COMPARATOR
Intervention: Platelet concentrates from CS-3000
Number of subjects: 115
Study 1725620 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet concentrates from AS-104 stored in teflon bags
Number of subjects: 115
Study 1725620 — intervention group
Group type: COMPARATOR
Intervention: Platelet concentrates from CS-3000 stored in polyolefine bags
Number of subjects: 115
Study 7074650 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) to supradiaphragmatic and infradiaphragmatic lymph node regions (total nodal irradiation)
Number of subjects: 261
Study 7074650 — intervention group
Group type: COMPARATOR
Intervention: RT plus chemotherapy (CT)
Number of subjects: 261
Study 30007330 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.018-inch slot bracket system
Number of subjects: 187
Study 30007330 — intervention group
Group type: COMPARATOR
Intervention: 0.022-inch slot bracket system
Number of subjects: 187
Study 28443790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates-based exercises along with standard exercise program
Number of subjects: 46
Study 28443790 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 46
Study 26598115 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 881
Study 24337434 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumbo forceps biopsy (8 mm); 4 endoscopic forceps biopsy specimens obtained.
Number of subjects: 148
Study 24337434 — intervention group
Group type: COMPARATOR
Intervention: Conventional forceps biopsy (6.8 mm); 4 endoscopic forceps biopsy specimens obtained.
Number of subjects: 148
Study 24337434 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the number of biopsies (2 or 4 EFBs); analyzed for concordance rate.
Number of subjects: 148
Study 24337434 — intervention group
Group type: EXPERIMENTAL
Intervention: High grade dysplasia analysis; evaluated in both groups.
Number of subjects: 148
Study 21412218 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-AGE diet
Number of subjects: 0
Study 21412218 — intervention group
Group type: EXPERIMENTAL
Intervention: Alagebrium treatment
Number of subjects: 0
Study 21412218 — intervention group
Group type: COMPARATOR
Intervention: High-AGE diet
Number of subjects: 0
Study 19643487 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-101 eye drops (86 microg/day)
Number of subjects: 40
Study 19643487 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-101 eye drops (43 microg/day)
Number of subjects: 40
Study 19643487 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-101 eye drops (172 microg/day)
Number of subjects: 40
Study 19643487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17584213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Highly Sensitive Search Strategy (HSSS) terms
Number of subjects: 285
Study 15105664 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% effort group
Number of subjects: 90
Study 15105664 — intervention group
Group type: COMPARATOR
Intervention: 60% effort group
Number of subjects: 90
Study 11903179 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoteridol (0.1 mmol/kg)
Number of subjects: 92
Study 11903179 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.1 mmol/kg)
Number of subjects: 92
Study 11903179 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoteridol
Number of subjects: 92
Study 11903179 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine
Number of subjects: 92
Study 9177871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 microgram of 1‐alpha‐hydroxyvitamin D3 with calcium (150 mg/day)
Number of subjects: 50
Study 9177871 — intervention group
Group type: COMPARATOR
Intervention: Calcium only (control group)
Number of subjects: 50
Study 7954417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorozole 1 mg
Number of subjects: 24
Study 7954417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorozole 2.5 mg
Number of subjects: 24
Study 7954417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorozole 5 mg
Number of subjects: 24
Study 7954417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorozole (all doses)
Number of subjects: 24
Study 3300966 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 54
Study 3300966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tamoxifen and fluoxymesterone
Number of subjects: 54
Study 3300966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant endocrine therapy)
Number of subjects: 54
Study 31639370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 14335
Study 31639370 — intervention group
Group type: COMPARATOR
Intervention: Cesarean section
Number of subjects: 14335
Study 31639370 — intervention group
Group type: COMPARATOR
Intervention: Nulliparous women
Number of subjects: 14335
Study 29452815 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Variable Ventilation (CVV)
Number of subjects: 50
Study 26636424 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index (≤45) with low percentage of carbohydrates (40% kcal)
Number of subjects: 163
Study 26636424 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index with high percentage of carbohydrates
Number of subjects: 163
Study 26636424 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of lowering glycemic index and increasing percentage of carbohydrates
Number of subjects: 163
Study 26636424 — intervention group
Group type: COMPARATOR
Intervention: High glycemic index (≥65) with high percentage of carbohydrates (58% kcal)
Number of subjects: 163
Study 24743493 — intervention group
Group type: EXPERIMENTAL
Intervention: Online post-dilution hemodiafiltration (HDF)
Number of subjects: 714
Study 24743493 — intervention group
Group type: COMPARATOR
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 714
Study 22577809 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site laparoscopic appendectomy
Number of subjects: 360
Study 22577809 — intervention group
Group type: COMPARATOR
Intervention: Three-port laparoscopic appendectomy
Number of subjects: 360
Study 20929123 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine for nourishing yin and clearing heat therapy (CM therapy)
Number of subjects: 60
Study 20929123 — intervention group
Group type: COMPARATOR
Intervention: Standard Western medical therapy
Number of subjects: 60
Study 18512767 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeat length (CAGn)
Number of subjects: 0
Study 18512767 — intervention group
Group type: COMPARATOR
Intervention: Age adjustment
Number of subjects: 0
Study 16459897 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 2
Study 16459897 — intervention group
Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 2
Study 16459897 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy problems
Number of subjects: 2
Study 16459897 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard problems
Number of subjects: 2
Study 14530064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac surgical procedures in African Americans
Number of subjects: 0
Study 10392729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal tissue plasminogen activator (tPA) 65-110 microg
Number of subjects: 26
Study 8704358 — intervention group
Group type: EXPERIMENTAL
Intervention: MFP-Ca (100 mg sodium monofluorophosphate + 500.5 mg Ca2+)
Number of subjects: 35
Study 8704358 — intervention group
Group type: COMPARATOR
Intervention: Ca tablet (500.5 mg Ca2+)
Number of subjects: 35
Study 2054405 — intervention group
Group type: EXPERIMENTAL
Intervention: Small cuff
Number of subjects: 181
Study 2054405 — intervention group
Group type: EXPERIMENTAL
Intervention: Large cuff
Number of subjects: 181
Study 2054405 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate cuff
Number of subjects: 181
Study 6341904 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (300 mg daily)
Number of subjects: 60
Study 6341904 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (0.96 g 12-hourly)
Number of subjects: 60
Study 6341904 — intervention group
Group type: COMPARATOR
Intervention: Sulphamethizole (1 g eight-hourly)
Number of subjects: 60
Study 30605952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBT-i)
Number of subjects: 75
Study 30605952 — intervention group
Group type: COMPARATOR
Intervention: Combination of CBT-i with tapered hypnotic agents
Number of subjects: 75
Study 29680779 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized vibration on quadriceps tendon
Number of subjects: 28
Study 29680779 — intervention group
Group type: COMPARATOR
Intervention: No vibration (control condition)
Number of subjects: 28
Study 26666448 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Asthma Education Intervention (EI) for 12 months
Number of subjects: 10
Study 26666448 — intervention group
Group type: COMPARATOR
Intervention: Delayed Asthma Education Intervention (DI) after 12 months observation
Number of subjects: 10
Study 24446385 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous insulin (biphasic insulin aspart) administered in relation to meals
Number of subjects: 0
Study 24446385 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian rhythm included in the model
Number of subjects: 0
Study 22129890 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab plus mitoxantrone/prednisone (M/P)
Number of subjects: 97
Study 22129890 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone/prednisone (M/P) alone
Number of subjects: 97
Study 20170477 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (AS-AQ)
Number of subjects: 1401
Study 20170477 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-sulphadoxine-pyrimethamine (AS-SP)
Number of subjects: 1401
Study 20170477 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-chlorproguanil-dapsone (AS-CD)
Number of subjects: 1401
Study 20170477 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-mefloquine (AS-MQ)
Number of subjects: 1401
Study 20170477 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DH-PP)
Number of subjects: 1401
Study 20170477 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AM-LM)
Number of subjects: 1401
Study 20170477 — intervention group
Group type: EXPERIMENTAL
Intervention: amodiaquine
Number of subjects: 1401
Study 20170477 — intervention group
Group type: EXPERIMENTAL
Intervention: amodiaquine-sulphadoxine-pyrimethamine (AQ-SP)
Number of subjects: 1401
Study 17638699 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg bevirimat
Number of subjects: 24
Study 17638699 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg bevirimat
Number of subjects: 24
Study 17638699 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg bevirimat
Number of subjects: 24
Study 17638699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15868998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg at 5 min before intubation
Number of subjects: 75
Study 15868998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg at 3 min before intubation
Number of subjects: 75
Study 15868998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg at 1 min before intubation
Number of subjects: 75
Study 15868998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg at 0.5 min before intubation
Number of subjects: 75
Study 15868998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg at 5, 3, 1, and 0.5 min before intubation
Number of subjects: 75
Study 15868998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 2 ml just before induction)
Number of subjects: 75
Study 15868998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg at 1 and 3 min before intubation
Number of subjects: 75
Study 12774058 — intervention group
Group type: COMPARATOR
Intervention: 10% DMSO
Number of subjects: 294
Study 12774058 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% DMSO/6% HES
Number of subjects: 294
Study 10563609 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Neuropathy Score (TNS)
Number of subjects: 35
Study 10563609 — intervention group
Group type: COMPARATOR
Intervention: Mayo Clinic measures of neuropathy, Neuropathy Symptom Score (NSS), Neurologic Impairment Score (NIS)
Number of subjects: 35